Table 1 Differences between demographic and clinicopathologic characteristics of MLM and non-MLM groups
Clinicopathologic Characteristics | n (%) | P | ||
|---|---|---|---|---|
MLM group (n = 75) | Non-MLM group (n = 218) | Total (n = 293) | ||
Gender | Â | Â | Â | .306 |
 Male | 40 (53.33) | 131 (60.09) | 171 (58.36) |  |
 Female | 35 (46.67) | 87 (39.91) | 122 (41.64) |  |
Age (years) | Â | Â | Â | .595 |
 ≤60 | 14 (18.67) | 47 (21.56) | 61 (20.82) |  |
 >60 | 61 (81.33) | 171 (78.44) | 232 (79.18) |  |
Family history of cancer | Â | Â | Â | .246 |
 No | 21 (28.00) | 77 (35.32) | 98 (33.45) |  |
 Yes | 54 (72.00) | 141 (64.68) | 195 (66.56) |  |
BMI | Â | Â | Â | .965 |
 ≤ 25 | 47 (62.67) | 136 (62.39) | 183 (62.46) |  |
 >25 | 28 (37.33) | 82 (37.61) | 110 (37.54) |  |
ALB | Â | Â | Â | .554 |
 Normal | 23 (30.67) | 75 (34.40) | 98 (33.45) |  |
 Abnormal | 52 (69.33) | 143 (65.60) | 195 (66.55) |  |
CEA | Â | Â | Â | .001 |
 Normal | 21 (28) | 111 (50.92) | 132 (45.05) |  |
 Abnormal | 44 (58.67) | 96 (44.04) | 140 (47.78) |  |
 Borderline | 10 (13.33) | 11 (5.05) | 21 (7.17) |  |
AFP | Â | Â | Â | .973 |
 Normal | 74 (98.67) | 213 (97.71) | 287 (97.95) |  |
 Abnormal | 1 (1.33) | 5 (2.29) | 6 (2.05) |  |
CA199 | Â | Â | Â | .683 |
 Normal | 5 (6.67) | 12 (5.50) | 17 (5.80) |  |
 Abnormal | 65 (86.67) | 196 (89.91) | 261 (89.08) |  |
 Borderline | 5 (6.67) | 10 (4.59) | 15 (5.12) |  |
Tumor primary location | Â | Â | Â | .510 |
 Ascending colon | 22 (29.33) | 63 (28.90) | 85 (29.01) |  |
 Transverse colon | 4 (5.33) | 8 (3.67) | 12 (4.10) |  |
 Descending colon | 30 (40.00) | 70 (32.11) | 100 (34.13) |  |
 Sigmoideum | 13 (17.33) | 57 (26.14) | 70 (23.89) |  |
 Boundary | 6 (8.00) | 20 (9.17) | 26 (8.87) |  |
Differentiation degree | Â | Â | Â | .113 |
 High | 6 (8.00) | 15 (6.88) | 21 (7.17) |  |
 High–medium | 3 (4.00) | 32 (14.68) | 35 (11.95) |  |
 Medium | 51 (68.00) | 143 (65.60) | 194 (66.21) |  |
 Medium–low | 11 (14.67) | 20 (9.17) | 31 (10.58) |  |
 Low | 4 (5.33) | 8 (3.67) | 12 (4.10) |  |
Max (cm) | Â | Â | Â | .727 |
 ≤ 5 | 43 (57.33) | 130 (59.63) | 173 (59.04) |  |
 >5 | 32 (42.67) | 88 (40.37) | 120 (40.96) |  |
Tissue infiltration | Â | Â | Â | .312 |
 No | 24 (32) | 84 (38.53) | 108 (36.86) |  |
 Yes | 51 (68) | 134 (61.67) | 185 (63.14) |  |
Vascular invasion | Â | Â | Â | <.001 |
 No | 40 (53.33) | 165 (75.69) | 205 (69.97) |  |
 Yes | 35 (46.67) | 53 (24.32) | 88 (30.03) |  |
Perineural invasion | Â | Â | Â | .937 |
 No | 53 (70.67) | 153 (70.19) | 206 (70.31) |  |
 Yes | 22 (29.33) | 65 (29.82) | 87 (29.69) |  |
pT | Â | Â | Â | .002 |
 pT1 | 1 (1.33) | 21 (9.63) | 22 (7.51) |  |
 pT2 | 12 (16.00) | 53 (24.31) | 65 (22.18) |  |
 pT3 | 32 (42.67) | 98 (44.95) | 130 (44.37) |  |
 pT4 | 30 (40.00) | 46 (21.10) | 76 (25.94) |  |
pN | Â | Â | Â | .064 |
 pN0 | 15 (20.00) | 68 (31.19) | 83 (28.33) |  |
 pN+ | 60 (80.00) | 150 (68.81) | 210 (71.67) |  |
Dukes | Â | Â | Â | .008 |
 A | 13 (17.33) | 74 (33.94) | 87 (29.69) |  |
 B | 14 (18.67) | 52 (23.85) | 66 (22.52) |  |
 C | 46 (61.33) | 86 (39.45) | 132 (45.05) |  |
 D | 2 (2.67) | 6 (2.75) | 8 (2.73) |  |
Kras mutation | Â | Â | Â | <.001 |
 Wild | 45 (60.00) | 176 (80.73) | 221 (75.43) |  |
 Mutation | 30 (40.00) | 42 (19.27) | 72 (24.57) |  |
Nras mutation | Â | Â | Â | .802 |
 Wild | 48 (64.00) | 143 (65.60) | 191 (65.19) |  |
 Mutation | 27 (36.00) | 75 (34.40) | 102 (34.81) |  |